Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutations
Phase 2
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-C000000184
- Lead Sponsor
- Hokkaido Lung Cancer Clinical Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
1.Serious concomitant systemic disorders 2.Uncontrollable angina, acute myocardial infarction or severe heart failure within 3 months 3.Uncontrollable diabetes mellitus or hypertension 4.Active infection 5.Interstitial pneumonia 6.Uncontrollable pleural effusion 7.Active ulcer 8.Active second malignancy 9.History of severe hypersensitivity 10.Severe SVC syndrome 11.Pregnancy 12.Other severe complication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Toxicity Survival